Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank100
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
6.97%
↑ 103% vs avg
Percentile
P100
Near historical high
Streak
4 yr
Consecutive growthExpanding
Average
-272.43%
Historical baseline
PeriodValueYoY Change
TTM6.97%+135.3%
2024-19.78%+84.2%
2023-124.87%+84.7%
2022-818.58%+25.5%
2021-1098.61%-781.9%
2020-124.57%-
20190.00%-
20180.00%-